XML 56 R18.htm IDEA: XBRL DOCUMENT
v3.25.2

Goodwill and Other Intangible Assets | 12 Months Ended
--- | ---
Apr. 25, 2025
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Other Intangible Assets | Goodwill and Other Intangible Assets Goodwill The following table presents the changes in the carrying amount of goodwill by segment:
(in millions) | Cardiovascular |  | Neuroscience |  | Medical Surgical |  | Diabetes |  | Total
April 28, 2023 | $ | 7,873 |  |  | $ | 11,718 |  |  | $ | 19,579 |  |  | $ | 2,255 |  |  | $ | 41,425 |
Goodwill as a result of acquisitions | 131 |  |  | — |  |  | — |  |  | — |  |  | 131 |
Purchase accounting adjustments | (5) |  |  | — |  |  | — |  |  | — |  |  | (5) |
Currency translation and other | (33) |  |  | (74) |  |  | (458) |  |  | — |  |  | (565) |
April 26, 2024 | 7,966 |  |  | 11,644 |  |  | 19,121 |  |  | 2,255 |  |  | 40,986 |
Goodwill as a result of acquisitions | — |  |  | — |  |  | 108 |  |  | — |  |  | 108 |
Purchase accounting adjustments | 2 |  |  | — |  |  | (2) |  |  | — |  |  | — |
Currency translation and other | 50 |  |  | 72 |  |  | 521 |  |  | 1 |  |  | 643 |
April 25, 2025 | $ | 8,017 |  |  | $ | 11,716 |  |  | $ | 19,748 |  |  | $ | 2,255 |  |  | $ | 41,737 |
The Company did not recognize any goodwill impairment charges during fiscal years 2025 or 2024. As a result of the agreement with DaVita, as disclosed in Note 3, the Company allocated $208 million of goodwill to the RCS business that met the criteria to be classified as held for sale during the first quarter of fiscal year 2023 and was subsequently sold on April 1, 2023. Upon allocation, a goodwill impairment test was performed for the RCS business, and the Company recognized $61 million of goodwill impairment charges during fiscal year 2023. The goodwill impairment charges are recognized in other operating (income) expense, net in the consolidated statements of income. Intangible Assets The following table presents the gross carrying amount and accumulated amortization of intangible assets:
| April 25, 2025 |  | April 26, 2024
(in millions) | Gross Carrying Amount |  | Accumulated Amortization |  | Gross Carrying Amount |  | Accumulated Amortization
Definite-lived: |  |  |  |  |  |  |
Customer-related | $ | 16,550 |  |  | $ | (9,650) |  |  | $ | 16,518 |  |  | $ | (8,689) |
Purchased technology and patents | 11,600 |  |  | (7,514) |  |  | 11,557 |  |  | (6,868) |
Trademarks and tradenames | 421 |  |  | (283) |  |  | 424 |  |  | (274) |
Other | 355 |  |  | (101) |  |  | 256 |  |  | (84) |
Total | $ | 28,925 |  |  | $ | (17,547) |  |  | $ | 28,755 |  |  | $ | (15,915) |
Indefinite-lived: |  |  |  |  |  |  |
IPR&D | $ | 289 |  |  | $ | — |  |  | $ | 385 |  |  | $ | — |
The Company did not recognize any definite-lived intangible asset impairment charges during fiscal years 2025 and 2023. During fiscal year 2024, the Company recognized $295 million of definite-lived intangible asset impairment charges in connection with the decision to exit its ventilator product line. The intangible asset impairment charges primarily related to purchased technology, customer-related intangibles, and trade names. The intangible asset impairment charges are recognized in other operating (income) expense, net in the consolidated statements of income. Refer to Note 3 for additional information on what led to the impairments in fiscal year 2024. There were no indefinite-lived intangible asset impairment charges during fiscal year 2025. Indefinite-lived intangible asset impairment charges were not significant for fiscal year 2024 and 2023. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of such clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future. Amortization Expense Intangible asset amortization expense was $1.8 billion for fiscal year 2025, including $151 million of accelerated amortization on certain intangible assets related to product line exits within the Cardiovascular Portfolio. Intangible asset amortization expense was $1.7 billion for fiscal years 2024 and 2023. Estimated aggregate amortization expense by fiscal year based on the current carrying value and remaining estimated useful lives of definite-lived intangible assets at April 25, 2025, excluding any possible future amortization associated with acquired IPR&D which has not met technological feasibility, is as follows:
(in millions) | Amortization Expense
2026 | $ | 1,677 |
2027 | 1,654 |
2028 | 1,582 |
2029 | 1,479 |
2030 | 1,343 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration